ceftaroline

ceftaroline. It is a fifth-generation cephalosporin antibiotic developed to combat serious bacterial infections caused by Gram-positive and Gram-negative organisms. This broad-spectrum agent is notable for its activity against methicillin-resistant ''Staphylococcus aureus'' (MRSA) and multidrug-resistant ''Streptococcus pneumoniae''. The drug is administered exclusively via intravenous therapy and is marketed under the brand names Teflaro and Zinforo following approval by regulatory bodies like the U.S. Food and Drug Administration and the European Medicines Agency.

Medical uses

Ceftaroline fosamil is indicated for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Its spectrum of activity includes key pathogens such as ''Streptococcus pneumoniae'', ''Staphylococcus aureus'' (including MRSA), ''Haemophilus influenzae'', ''Klebsiella pneumoniae'', and ''Escherichia coli''. Clinical trials, including the FOCUS and CANVAS programs, demonstrated its non-inferiority to comparator regimens like ceftriaxone plus vancomycin. It is not effective against infections caused by ''Pseudomonas aeruginosa'' or ''Enterobacter'' species that produce certain beta-lactamase enzymes.

Adverse effects

Common adverse reactions observed in clinical studies include diarrhea, nausea, rash, and insomnia. Serious but less frequent events can involve hypersensitivity reactions, including anaphylaxis, and ''Clostridioides difficile''-associated diarrhea. Hematologic abnormalities such as neutropenia and thrombocytopenia have been reported. As with other broad-spectrum antibiotics, use may result in the development of drug resistance and superinfection with non-susceptible organisms like ''Candida albicans''. Monitoring of renal function is recommended in patients with pre-existing kidney disease.

Pharmacology

Ceftaroline fosamil is a prodrug that is rapidly converted in vivo to the active metabolite ceftaroline. It exerts its bactericidal effect by binding to and inhibiting essential penicillin-binding proteins (PBPs), including PBP2a in MRSA, which confers resistance to other beta-lactam agents. The drug demonstrates time-dependent killing and exhibits a low potential for cytochrome P450 interactions. Its volume of distribution approximates total body water, and it is primarily eliminated unchanged via glomerular filtration in the kidney, with a terminal half-life of approximately 2.6 hours. Dosage adjustments are required for patients with moderate to severe renal impairment.

History

The development of ceftaroline was driven by the urgent need for new agents against resistant Gram-positive pathogens. It was discovered and developed by the Japanese pharmaceutical company Takeda. The global rights were later acquired by Forest Laboratories (now part of AbbVie). The U.S. Food and Drug Administration approved ceftaroline fosamil under the name Teflaro in 2010 based on data from the pivotal FOCUS and CANVAS clinical trials. The European Medicines Agency granted marketing authorization for Zinforo in 2012. Its development represents a significant milestone in the antibiotic arms race against multidrug resistance.

Society and culture

Ceftaroline is considered a critically important antibiotic within frameworks established by the World Health Organization. Its high cost and status as a newer agent have led to discussions about antibiotic stewardship and access within healthcare systems like the National Health Service (NHS). The drug has been the subject of post-marketing surveillance studies, including the Ceftaroline Observational Study (CORE). While it is protected by patents, its role in treating infections caused by organisms like community-associated MRSA has solidified its place in hospital formularies, often reserved for cases where alternatives like vancomycin or daptomycin are unsuitable.

Category:Cephalosporin antibiotics Category:World Health Organization essential medicines